Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538778 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL18702790 | 0.84 | ALDH1A1 (0.60) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL4845134 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL13664958 | 0.83 | SMN1; SMN2 (0.64) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL2776017 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL10153796 | 0.83 | SMN1; SMN2 (0.72) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL10506317 | 0.82 | SMN1; SMN2 (0.60) | ALDH1A1HPGDTSHRSMN1; SMN2NPSR1 | |
| SCHEMBL18496531 | 0.82 | NPC1 (0.56) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL1279945 | 0.81 | SMN1; SMN2 (0.63) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL7000350 | 0.80 | RAB9A (0.80) | ALDH1A1HPGDTSHRSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035622-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| WO-2020142729-A1 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | BellBrook Labs (US) | 2020-07-09 | — | — | WO | disclosed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| EP-1678166-B1 | PROTEIN KINASE INHIBITORS | UNIV ARIZONA (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090143399-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090099165-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080051414-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-28 | — | — | US | disclosed |
| US-7335662-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-26 | — | — | US | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326713-B2 | Substituted tricyclic compound as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-5679683-A | USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS | WARNER-LAMBERT COMPANY (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099165-A1 | Protein Kinase Inhibitors | CDK2, MAP3K1, MAP3K2 | ALDH1A1 2994/4885HPGD 2157/4885TSHR 2097/4885 |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | ALDH1A1 2189/4885HPGD 3589/4885TSHR 2133/4885 |
| US-20080051414-A1 | Protein Kinase Inhibitors | CDK2, MAP3K1, MAP3K2 | ALDH1A1 2994/4885HPGD 2157/4885TSHR 2097/4885 |
| US-20090143399-A1 | Protein Kinase Inhibitors | CDK2, MAP3K1, MAP3K2 | ALDH1A1 2994/4885HPGD 2157/4885TSHR 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.